About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/28/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/28/2021.

Photobiomodulation Therapy for the Prevention of Acute Radiodermatitis in Breast Cancer Patients Undergoing Radiotherapy

Clinicaltrials.gov identifier NCT03924011

Recruitment Status Recruiting

First Posted April 23, 2019

Last update posted April 23, 2019

Study Description

Brief summary:

Radiodermatitis (RD), an inflammatory skin reaction, occurs in more than 90 percent of cancer patients treated with radiotherapy (RT). This is the result of the radiation causing damage to the epidermal basal skin stem cells. Based on the severity of the skin symptoms, acute RD can be categorized into four grades ranging from red and dry skin to moist desquamation, necrosis, and eventually ulceration. Acute RD can be distressing, negatively influencing the patients' quality of life (QOL). In cases of severe RD, RT might be interrupted, affecting the treatment outcome. Currently, there is no generally accepted treatment available for RD. As such, the standard skincare treatment is hospital dependent. Photobiomodulation therapy (PBMT) can offer a solution, since the therapeutic use of (infra)red light induces photochemical reactions in the target cells, stimulating repair and healing processes, and reducing pain and inflammation. Previous studies using PBMT to prevent RD showed promising results. However, these beneficial results need to be validated in a larger breast cancer patient population receiving an alternative RT regimen. The study hypothesizes that PBMT is a safe and effective strategy to prevent worsening of acute RD grade two or higher in breast cancer patients undergoing RT. The primary objective is to measure the degree of acute RD to detect changes during and after RT. Second, the patients' QOL and pain will be assessed. Finally, the third objective is to evaluate the safety of PBMT. The results of this project will support the implementation of PBMT into the standard RD skincare program.

  • Condition or Disease:Radiodermatitis
    Breast Cancer
  • Intervention/Treatment: Device: Photobiomodulation therapy (PBMT)
    Device: Sham laser
  • Phase: N/A
Detailed Description

N/A

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 100 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Double (Participant, Outcomes Assessor)
  • Primary Purpose: Prevention
  • Official Title: The Use of Photobiomodulation Therapy for the Prevention of Acute Radiodermatitis in Breast Cancer Patients: a Multicentre, Randomized, Placebo-controlled Trial
  • Actual Study Start Date: February 2019
  • Estimated Primary Completion Date: February 2021
  • Estimated Study Completion Date: June 2021
Arms and interventions
Arm Intervention/treatment
Experimental: Treatment group
Receives PBMT (2x/week) in combination with standard skin care starting from day 1 of radiotherapy
Device: Photobiomodulation therapy (PBMT)
PBMT sessions will be planned 2x/week after RT.
Sham Comparator: Control group
Receives sham laser (2x/week) in combination with standard skin care starting from day 1 of radiotherapy
Device: Sham laser
Sham laser sessions will be applied 2x/week after RT.
Outcome Measures
  • Primary Outcome Measures: 1. Radiation Dermatitis Grade [ Time Frame: week 1 ]
    Objective scoring of the severity of radiation dermatitis using the grading system of the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/ EORTC) objective scoring of the severity of radiation dermatitis using the grading system of the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/ EORTC)
  • 2. Radiation Dermatitis Grade [ Time Frame: week 2 ]
    Objective scoring of the severity of radiation dermatitis using the grading system of the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/ EORTC) objective scoring of the severity of radiation dermatitis using the grading system of the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/ EORTC)
  • 3. Radiation Dermatitis Grade [ Time Frame: week 3 ]
    Objective scoring of the severity of radiation dermatitis using the grading system of the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/ EORTC) objective scoring of the severity of radiation dermatitis using the grading system of the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/ EORTC)
  • 4. Radiation Dermatitis Grade [ Time Frame: week 4 ]
    Objective scoring of the severity of radiation dermatitis using the grading system of the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/ EORTC) objective scoring of the severity of radiation dermatitis using the grading system of the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/ EORTC)
  • 5. Radiation Dermatitis Grade [ Time Frame: week 5 ]
    Objective scoring of the severity of radiation dermatitis using the grading system of the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/ EORTC) objective scoring of the severity of radiation dermatitis using the grading system of the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/ EORTC)
  • 6. Radiation Dermatitis Grade [ Time Frame: week 6 ]
    Objective scoring of the severity of radiation dermatitis using the grading system of the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/ EORTC) objective scoring of the severity of radiation dermatitis using the grading system of the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/ EORTC)
  • 7. Radiation Dermatitis Assessment [ Time Frame: week 1 ]
    Radiation dermatitis assessment scale (Radiation-Induced Skin Reaction Assessment Scale, RISRAS)
  • 8. Radiation Dermatitis Assessment [ Time Frame: week 2 ]
    Radiation dermatitis assessment scale (Radiation-Induced Skin Reaction Assessment Scale, RISRAS 0-4)
  • 9. Radiation Dermatitis Assessment [ Time Frame: week 3 ]
    Radiation dermatitis assessment scale (Radiation-Induced Skin Reaction Assessment Scale, RISRAS 0-4)
  • 10. Radiation Dermatitis Assessment [ Time Frame: week 4 ]
    Radiation dermatitis assessment scale (Radiation-Induced Skin Reaction Assessment Scale, RISRAS 0-4)
  • 11. Radiation Dermatitis Assessment [ Time Frame: week 5 ]
    Radiation dermatitis assessment scale (Radiation-Induced Skin Reaction Assessment Scale, RISRAS 0- 4)
  • 12. Radiation Dermatitis Assessment [ Time Frame: week 6 ]
    Radiation dermatitis assessment scale (Radiation-Induced Skin Reaction Assessment Scale, RISRAS (0 - 4)
  • Secondary Outcome Measures: 1. Pain evaluation: VAS [ Time Frame: week 1 ]
    Patients' pain due to radiodermatitis will be evaluated using the visual analogue scale (VAS 0-10). A VAS is a laminated plastic with descriptors at each end. The patients will be asked to move the sliding marker along the plastic to indicate their subjective experience of pain. Each mark is associated with a certain pain score. A VAS is a well documented, valid, and frequently used measure of pain intensity.
  • 2. Pain evaluation: VAS [ Time Frame: week 2 ]
    Patients' pain due to radiodermatitis will be evaluated using the visual analogue scale (VAS 0-10). A VAS is a laminated plastic with descriptors at each end. The patients will be asked to move the sliding marker along the plastic to indicate their subjective experience of pain. Each mark is associated with a certain pain score. A VAS is a well documented, valid, and frequently used measure of pain intensity.
  • 3. Pain evaluation: VAS [ Time Frame: week 3 ]
    Patients' pain due to radiodermatitis will be evaluated using the visual analogue scale (VAS 0-10). A VAS is a laminated plastic with descriptors at each end. The patients will be asked to move the sliding marker along the plastic to indicate their subjective experience of pain. Each mark is associated with a certain pain score. A VAS is a well documented, valid, and frequently used measure of pain intensity.
  • 4. Pain evaluation: VAS [ Time Frame: week 4 ]
    Patients' pain due to radiodermatitis will be evaluated using the visual analogue scale (VAS 0-10). A VAS is a laminated plastic with descriptors at each end. The patients will be asked to move the sliding marker along the plastic to indicate their subjective experience of pain. Each mark is associated with a certain pain score. A VAS is a well documented, valid, and frequently used measure of pain intensity.
  • 5. Pain evaluation: VAS [ Time Frame: week 5 ]
    Patients' pain due to radiodermatitis will be evaluated using the visual analogue scale (VAS 0-10). A VAS is a laminated plastic with descriptors at each end. The patients will be asked to move the sliding marker along the plastic to indicate their subjective experience of pain. Each mark is associated with a certain pain score. A VAS is a well documented, valid, and frequently used measure of pain intensity.
  • 6. Pain evaluation: VAS [ Time Frame: week 6 ]
    Patients' pain due to radiodermatitis will be evaluated using the visual analogue scale (VAS 0-10). A VAS is a laminated plastic with descriptors at each end. The patients will be asked to move the sliding marker along the plastic to indicate their subjective experience of pain. Each mark is associated with a certain pain score. A VAS is a well documented, valid, and frequently used measure of pain intensity.
  • 7. Quality of life assessment [ Time Frame: week 1 ]
    The Skindex-16 questionnaire will be used to assess patients quality of life. This is the most appropriate questionnaire that accurately and sensitively measures to what extent the patients' life is affected by their skin condition.
  • 8. Quality of life assessment [ Time Frame: week 2 ]
    The Skindex-16 questionnaire will be used to assess patients quality of life. This is the most appropriate questionnaire that accurately and sensitively measures to what extent the patients' life is affected by their skin condition.
  • 9. Quality of life assessment [ Time Frame: week 3 ]
    The Skindex-16 questionnaire will be used to assess patients quality of life. This is the most appropriate questionnaire that accurately and sensitively measures to what extent the patients' life is affected by their skin condition.
  • 10. Quality of life assessment [ Time Frame: week 4 ]
    The Skindex-16 questionnaire will be used to assess patients quality of life. This is the most appropriate questionnaire that accurately and sensitively measures to what extent the patients' life is affected by their skin condition.
  • 11. Quality of life assessment [ Time Frame: week 5 ]
    The Skindex-16 questionnaire will be used to assess patients quality of life. This is the most appropriate questionnaire that accurately and sensitively measures to what extent the patients' life is affected by their skin condition.
  • 12. Quality of life assessment [ Time Frame: week 6 ]
    The Skindex-16 questionnaire will be used to assess patients quality of life. This is the most appropriate questionnaire that accurately and sensitively measures to what extent the patients' life is affected by their skin condition.
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: Female
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Informed Consent as documented by signature

- Diagnosis of non-invasive (stage 0) or invasive (stage 1, 2 and 3A) breast
adenocarcinoma

- Treatment with primary breast-sparing surgery (lumpectomy) and/or neoadjuvant
(preoperative) or adjuvant (postoperative) chemotherapy or hormonal therapy

- Scheduled for postoperative radiotherapy at Ziekenhuis Oost-Limburg, Genk:

- Hypofractionated radiotherapy regimen (i.e. 16 daily fractions of 2.66 Gray to the
whole breast followed by a boost of 5 fractions of 2.66 Gray to the tumor bed,
5x/week)

Exclusion Criteria:

- Scheduled for postoperative radiotherapy at Jessa Hospital, Hasselt, Belgium

- Previous irradiation to the same breast

- Metastatic disease

- Concurrent chemotherapy

- Required use of bolus material to deliver radiotherapy (i.e material placed on the
to-be- irradiated zone to modulate the delivered dose in order to ensure an optimal
distribution of the radiation dose; mostly used for treatment of superficial tumors)

- Known or suspected non-compliance, drug or alcohol abuse

- Inability to follow the procedures of the study, e.g. due to language problems,
psyschological disorders, dementia, etc. of the participant

- Seizure

- Disorders triggered by lighttake anticoagulants

- Hemorrhagic diatheses

- Pregnancy

- Suspected of carrying serious infectious disease

- HIV positive history

Contacts and Locations
Contacts

Contact: Jeroen Mebis, Prof. Dr. 003211 33 79 79 jeroen.mebis@jessazh.be

Contact: Jolien Robijns, PhD 003211337229 jolien.robijns@uhasselt.be

Locations

Belgium, Limburg
Ziekenhuis Oost-Limburg Campus St.-Jan
Genk

Belgium
Jessa Ziekenhuis
Hasselt

Sponsors and Collaborators

Hasselt University

Jessa Hospital

Ziekenhuis Oost-Limburg

Investigators

Study Director: Jolien Robijns, PhD Hasselt University

More Information
  • Responsible Party: Hasselt University
  • ClinicalTrials.gov Identifier: NCT03924011 History of Changes
  • Other Study ID Numbers: 75
  • First Posted: April 23, 2019 Key Record Dates
  • Last Update Posted: April 23, 2019
  • Last Verified: April 2019
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Hasselt University: Radiodermatitis
    Breast cancer
    Radiotherapy
    Photobiomodulation therapy
    Low-level light therapy
    Skin diseases
    Radiation injuries
    Wounds and injuries
    Oncology
  • Additional relevant MeSH terms: Breast Neoplasms Radiodermatitis